Ireland· IE-PA-PA2315/092/004
Gemcitabine 100 mg/ml Concentrate for Solution for Infusion
A gemcitabine product containing gemcitabine, registered in Ireland by Accord Healthcare Ireland Ltd.. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Gemcitabine is registered in 17 of 19 countries.
Countries holding a registration under ATC L01BC05 (gemcitabine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Gemcitabine · ATC L01BC05
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of gemcitabine costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Gemcitabine · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$27.60
The record
At a glance
HPRA (Ireland)- Active substance
- Gemcitabine
- Manufacturer
- Accord Healthcare Ireland Ltd.
- Country
- Ireland (IE)
- ATC code
- L01BC05
- ATC class
- Gemcitabine
- Defined daily dose
- 0.2 g, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA2315/092/004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
370 interactions on record for gemcitabine.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gemcitabine · interactions on record
370 records
- 33 severe
- 114 moderate
- 19 minor
- 204 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Gemcitabine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumGemcitabine Accord Healthcare 100 mg/mlAccord Healthcare
- CzechiaGEMCITABINE ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- NorwayGemcitabine AccordAccord Healthcare B.V.
- PolandGemcitabinum AccordAccord Healthcare Polska Sp. z o.o.
- SwedenGemcitabine Accord 100 mg/ml Koncentrat till infusionsvätska, lösningAccord Healthcare B.V.
- FinlandGemcitabine AccordAccord Healthcare B.V.
- SwitzerlandGemcitabin Accord 1500 mg/15 ml, Konzentrat zur Herstellung einer InfusionslösungAccord Healthcare AG
- United KingdomGemcitabine 1.2g/120ml infusion bagsSun Pharma UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Gemcitabin Accord, Gemcitabin Ebewe
- Belgium · Gemcitabin Sandoz, Gemcitabin Sun
- Bulgaria · Гемсол, Гемцитабин Акорд
- Cyprus · Gemcitabine Accord, Gemnil
- Czechia · Gemcitabin Ebewe, Gemcitabin Sun
- Germany · Bendacitabin, Gemci-Cell
- Denmark · Gemcitabin "sandoz", Gemcitabin Accord
- Estonia · Gemcitabine Accord, Gemcitabine Kabi
- Spain · Gemcitabina Accord, Gemcitabina Aurovitas Spain
- Finland · Gemcitabin Accord, Gemcitabin Sandoz
- France · Gemcitabine Accord, Gemcitabine Arrow
- United Kingdom (Northern Ireland) · Gemcitabine Accord Healthcare, Gemcitabine Ennogen Ip
- Greece · Demozar, Gemcipen
- Croatia · Gemcitabin Accord, Gemcitabin Sandoz
- Hungary · Gemcitabin Kabi, Gemcitabine Accord
- Iceland · Gemcitabin Wh, Gemkabi
- Italy · Gemcitabina Accord, Gemcitabina Aurobindo Pharma Italia
- Lithuania · Gemcitabine Accord, Gemcitabine Kabi
- Luxembourg · Gemcitabine Eg, Gemcitabine Eugia
- Latvia · Gemcitabine Accord, Gemcitabine Kabi
- Malta · Gemcitabine Pfizer Hellas, Gemnil
- Netherlands · Gemcitabine Accord, Gemcitabine Fresenius Kabi
- Norway · Gemcitabin Sandoz, Gemcitabin Sun
- Poland · Gemcitabine Kabi, Gemcitabinum Accord
- Portugal · Gemcit, Gemcitabina Accord
- Romania · Gemcitabină Accord, Gemcitabina Kabi
- Sweden · Gemcitabin Sandoz, Gemcitabin Sun
- Slovenia · Gemcitabin Accord, Gemcitabin Kabi
- Slovakia · Gemcitabín Sun, Gemcitabine Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/16cd2fb6-9711-4921-8a71-4a9bea2e7c37 GET /v1/drugs/16cd2fb6-9711-4921-8a71-4a9bea2e7c37?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01BC",
"L01BC05"
],
"strength": null,
"pa_number": "PA2315/092/004",
"substances": [
"Gemcitabine"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "09/03/2012",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about gemcitabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.